REPLY: “From Cloud to Edge” Research Predicts the Rise of Edge Computing and Unveils the Main Trends in the Cloud Computing Market
2.2.2021 12:00:00 EET | Business Wire | Press release
By 2025 Cloud Computing will lead the ICT infrastructure market and Edge Computing will become an exponentially growing market, according to Reply’s new research “From Cloud to Edge”, made possible by Reply’s Trend SONAR proprietary data-driven platform and the support of Teknowlogy Group.
The research explores the use of both Cloud Computing and Edge Computing technologies in “Europe-5” (Italy, Germany, France, Netherlands, Belgium), and “Big-5” (USA, United Kingdom, Brazil, China, India) clusters in order to understand the evolution of the market.
In the next 5 five years Edge Computing will be an exponentially growing market in all “Europe-5” and “Big-5” clusters’ countries. Germany will be the biggest European market for both Cloud Computing and Edge Computing; the USA will be the dominant market worldwide.
The growing usage of IoT solutions, the closer combination of Information Technology and Operational Technology and the integration of Industrial Control Systems in the IT stack, as well as future 5G campus solutions for low-latency applications, are accelerating the need for edge solutions.
In fact, Edge Computing can support companies with computing tasks that cannot be done in the cloud and offers clear advantages when dealing with low latency, connectivity, security or privacy and transmitted data volumes are an issue.
Edge and distributed cloud architectures will increase the speed of data processing and reduce time lag. Edge computing, alone or in combination with Cloud Computing, will play a key role to enable technologies like autonomous vehicles, digital factories, smart cities, digital health, smart tracking and much more.
Hybrid models like Edge Cloud will be pushed by the hyperscalers and the wide 5G rollout will give Telcos and their service partners a relevant role in the new ecosystem, especially thanks to mobile-edge computing which is able to ensure very low latency without local infrastructure, with compute units not on-premise but extremely close from to a cell tower.
“Edge computing is here to stay. It is already starting to reshape enterprise computing and it can play a vital role in IT architectures. All the industries that need to perform the computing tasks as close to where data is gathered as possible will benefit from Edge Computing. At Reply, we’re already supporting global enterprises to design and implement architectures that leverage the best of Edge and Cloud Computing, while ensuring privacy and cybersecurity” commented Filippo Rizzante, CTO Reply.
In addition, the research indicates that Cloud Computing became the most popular ICT focus during Coronavirus peaks. COVID-19 has intensified the global spread of Cloud Computing technologies after 15 years of steady growth: across the world, millions of users started to use cloud-based platforms to collaborate, shop online, and for entertainment purposes.
Cloud technologies are key to being able to react and restart activities. By 2021 in both “Europe-5” and “Big-5” clusters the Infrastructure as a Service (IaaS)/Platform as a Service (PaaS) market will grow - in all scenarios - between 50% and 55% (vs. 2019).
The Software as a Service (SaaS) market is also set to grow rapidly in every country analysed. In particular, by 2025 it is predicted to double in the USA, UK and all “Europe-5” cluster countries, while likely to quadruple in India and China.
For more insights download the full research “From Cloud To Edge”.
Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005054/en/
Contact information
Media
Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594
Aaron Miani
a.miani@reply.com
Tel. +44 (0)20 7730 6000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 09:50:00 EET | Press release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU ® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 09:30:00 EET | Press release
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The application is based on data from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. In the trial, ENHERTU demo
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 09:00:00 EET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term commitment to the Italian market, where the company has deep industrial roots
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 03:18:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
Perpetual Atomics Ltd, QSA Europe, QSA Global and Reef Origin to Collaborate on Building Radioisotope Power Systems in Europe18.2.2026 17:44:00 EET | Press release
Perpetual Atomics Ltd, QSA Europe (a trading name of Loma Systems s.r.o.), QSA Global, Inc., and Reef Origin signed an MOU in Prague to collaborate on the industrialized production of radioisotope power systems in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218036211/en/ Teams from Perpetual Atomics & QSA Global (USA and Czechia) at the facilities in Czechia This MOU builds on the existing collaboration between QSA Global, Inc. and Perpetual Atomics Ltd by expanding and strengthening the capacity and capability to produce radioisotope power systems in Europe. The key partnership with QSA Europe provides access to existing facilities, capabilities, knowledge, and know-how for the storage, handling, and distribution of commercial radioisotope systems for terrestrial applications. This capability is directly transferable to radioisotope power technologies for space. Radioisotope and nuclear power technologies are
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom